ImmunoGenesis
ImmunoGenesis is a clinical-stage biotechnology company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company develops science-driven immunotherapies specifically designed to treat 'cold' tumors that lack activated T cells or have other immune resistance mechanisms. Their mission is to create therapies that address the pathology of these tumors, transforming them into 'hot' tumors to elicit a robust immune response. They are actively developing a pipeline of therapies, including novel antibodies and agents like evofosfamide, to overcome immune resistance and improve outcomes for patients with difficult-to-treat cancers.
Industries
Nr. of Employees
small (1-50)
ImmunoGenesis
JLABS @ TMC, 2450 Holcombe Blvd, Suite J, Houston, TX 77021
Patents
Products
Dual‑specific PD‑1 pathway blocking antibody with engineered effector function (clinical‑stage)
A bispecific antibody designed to block both PD‑1 pathway ligands and incorporate engineered effector function to enable depletion of immunosuppressive cells in the tumor microenvironment; evaluated in early‑phase clinical studies as monotherapy and in combinations.
Hypoxia‑activated prodrug for tumor hypoxia reversal (clinical‑stage)
A nitroimidazole‑based prodrug approach that reduces tumor hypoxia via tissue remodeling and vascular restoration to enable T‑cell infiltration and sensitize tumors to checkpoint inhibition; supported by early clinical data in combination with checkpoint blockade.
Antibody‑conjugated STING agonist for systemic tumor targeting (preclinical‑stage)
An antibody‑based conjugate that links a synthetic STING agonist to a tumor‑targeting antibody to enable intravenous systemic delivery of a potent innate immune agonist to tumor sites and specific cells within the tumor microenvironment.
Dual‑specific PD‑1 pathway blocking antibody with engineered effector function (clinical‑stage)
A bispecific antibody designed to block both PD‑1 pathway ligands and incorporate engineered effector function to enable depletion of immunosuppressive cells in the tumor microenvironment; evaluated in early‑phase clinical studies as monotherapy and in combinations.
Hypoxia‑activated prodrug for tumor hypoxia reversal (clinical‑stage)
A nitroimidazole‑based prodrug approach that reduces tumor hypoxia via tissue remodeling and vascular restoration to enable T‑cell infiltration and sensitize tumors to checkpoint inhibition; supported by early clinical data in combination with checkpoint blockade.
Antibody‑conjugated STING agonist for systemic tumor targeting (preclinical‑stage)
An antibody‑based conjugate that links a synthetic STING agonist to a tumor‑targeting antibody to enable intravenous systemic delivery of a potent innate immune agonist to tumor sites and specific cells within the tumor microenvironment.
Services
Sponsorship and operational management of first‑in‑human and early‑phase oncology clinical trials including protocol execution, safety monitoring, PK/immunogenicity assessment, and site coordination.
Preclinical pharmacology, mechanism‑of‑action, and translational studies using orthotopic and veterinary models to support clinical translation and biomarker discovery.
Translational biomarker analyses correlating immune and metabolic gene signatures with clinical response to support patient selection and mechanistic endpoints.
In‑licensing of academic discoveries and acquisition of clinical‑stage assets to assemble complementary therapeutic programs and support pipeline growth.
Operation of a translational research laboratory to perform preclinical studies and biomarker work, combined with development of CMC and quality programs to support clinical timelines.
Sponsorship and operational management of first‑in‑human and early‑phase oncology clinical trials including protocol execution, safety monitoring, PK/immunogenicity assessment, and site coordination.
Preclinical pharmacology, mechanism‑of‑action, and translational studies using orthotopic and veterinary models to support clinical translation and biomarker discovery.
Translational biomarker analyses correlating immune and metabolic gene signatures with clinical response to support patient selection and mechanistic endpoints.
In‑licensing of academic discoveries and acquisition of clinical‑stage assets to assemble complementary therapeutic programs and support pipeline growth.
Operation of a translational research laboratory to perform preclinical studies and biomarker work, combined with development of CMC and quality programs to support clinical timelines.
Expertise Areas
- Immuno‑oncology for immune‑excluded (cold) tumors
- Early‑phase clinical trial management (Phase 1/2)
- Bispecific/dual‑specific antibody engineering
- Antibody‑mediated targeted delivery of immune agonists
Key Technologies
- Dual‑specific/bispecific monoclonal antibody engineering
- Antibody‑agonist conjugation (targeted immune agonist delivery)
- Synthetic STING agonists (cyclic dinucleotide agonists)
- Hypoxia‑activated prodrugs
News & Updates
ImmunoGenesis will present updates on its Phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic function, at ASCO 2025.
The company has expanded its clinical trial of IMGS-001 to Ochsner MD Anderson Cancer Center to accelerate progress and offer more patients access to this approach.
The company will participate in the NeauxCancer Conference, discussing its pipeline and clinical progress.
The company will present updates on its Phase 1a/1b clinical trial of IMGS-001 at ASCO 2025.
The trial expansion aims to evaluate IMGS-001 in more patients and tumor types.
The presentation will cover the company's pipeline and clinical progress.
ImmunoGenesis will present updates on its Phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic function, at ASCO 2025.
The company has expanded its clinical trial of IMGS-001 to Ochsner MD Anderson Cancer Center to accelerate progress and offer more patients access to this approach.
The company will participate in the NeauxCancer Conference, discussing its pipeline and clinical progress.
The company will present updates on its Phase 1a/1b clinical trial of IMGS-001 at ASCO 2025.
The trial expansion aims to evaluate IMGS-001 in more patients and tumor types.
The presentation will cover the company's pipeline and clinical progress.